DBDavid E. Burdette

David E. Burdette

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David E. Burdette has a total of 266 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Magnetoencephalography (MEG) Augments Semiology in Stereotactic Electroencephalography (SEEG) Evaluations

    by Andrew J. Zillgitt, Garnett C. Smith, David E. Burdette, Cesar A. Serrano Almeida, Anant Krishnan, Michael D. Staudt, Paul Ferrari

    The foundation of a successful stereotactic electroencephalography (SEEG) evaluation has remained relatively unchanged since the first SEEG implantation in 1957 and is predicated on a robust semiology-driven hypothesis. Although epilepsy presurgical evaluation has expanded since the 1950s with the introduction of new technology, e.g., brain magnetic resonance imaging (MRI), few, if any, noninvasive diagnostic studies provide significant complementary information to the epilepsy presurgical evaluation as magnetoencephalography (MEG). As SEEG becomes increasingly ubiquitous as the intracranial EEG modality of choice for more comprehensive epilepsy centers, the importance of MEG in the epilepsy presurgical evaluation also increases. In this review, the use of MEG in addition to seizure semiology in the development of an SEEG implantation strategy will be reviewed and illustrated with two representative cases. Finally, within this review, epilepsy surgical outcomes from presurgical evaluations that incorporated MEG will be discussed.

  • Open Access

    Responsive neurostimulation (RNS) programming

    by Philip M. McCarthy, David E. Burdette


  • Open Access

    Postapproval Study for Brain-Responsive Neurostimulation for Drug-Resistant Focal Epilepsy

    by Dawn Eliashiv, Vikram R. Rao, Barbara C. Jobst, Jerzy P. Szaflarski, John D. Rolston, Lesley C. Kaye, Taneeta Mindy Ganguly, Katie Bullinger, Patricia C. Dugan, David E. Burdette, et al.

    Background and ObjectivesNeuromodulation therapies are approved for the treatment of focal epilepsy based on data from randomized controlled trials (RCTs). After approval of a responsive direct bra...


  • Open Access

    Clusters in Thalamic iEEG Spectral Features Reveal Sleep/Wake Differences Over Time

    by David Burdette, Sanjay Patra, Martha Morrell, Lise Johnson

    Purpose: The thalamus is a target for neurostimulation in epilepsy based on its extensive reciprocal connectivity with the cortex and subcortical areas and putative participation in a broader seizure network. In focal neocortical onset epilepsies, costimulation of the cortex and thalamus may provide an opportunity to modulate two nodes of a seizure network. Given the central role of the thalamus in sleep oscillations and regulation of consciousness, as well as the fundamental interaction between sleep and epilepsy, consideration of sleep/wake cycles may be important when treating patients with corticothalamic stimulation. Methods: This single-center retrospective study included 30 patients with focal seizures treated with cortical and thalamic responsive neurostimulation (NeuroPace RNS ® System). The thalamic leads were implanted in the centromedian, pulvinar, mediodorsal, or anterior nucleus depending on clinical characteristics, semiology, and localization testing. Changes in the average power of predefined frequency bands in the interictal thalamic iEEGs were evaluated in ambulatory daily recordings collected postimplant. Results: Two clusters in frequency characteristics were clearly distinguished by time of day (daytime vs. nighttime). The time series evolution for points in the two clusters was not generally correlated, and sometimes diverged. Clusters were more prominent on some channels than others, even between adjacent electrode contacts on the same leads, perhaps reflecting the anatomic location. Conclusions: These results suggest that thalamic iEEG data can potentially be used to identify wake/sleep states electrographically without traditional sleep studies. This could enable state-dependent neuromodulation therapy. The observed changes in sleep/wake clusters over time could represent neuromodulation-driven changes in thalamocortical networks and warrant further investigation.


  • Open Access

    Corticothalamic Responsive Neurostimulation for Focal Epilepsy: A Single-Center Experience

    by David Burdette, Sanjay Patra, Lise Johnson

    Purpose: Owing to its extensive, reciprocal connectivity with the cortex and other subcortical structures, the thalamus is considered an important target for neuromodulation in drug-resistant focal epilepsy. Using corticothalamic stimulation, it is possible to modulate both the thalamus and the cortical seizure onset zone. Limited published clinical experience describes corticothalamic stimulation with depth leads targeting one of the anterior (ANT), centromedian (centromedian nucleus), or pulvinar (PUL) thalamic nuclei. However, it is not clear which of these nuclei is the “best” therapeutic target. Methods: This study comprised a single-center experience with corticothalamic responsive neurostimulation using the RNS System to target these three thalamic nuclei. Presented here are the methods for target selection and device programming as well as clinical outcomes and a comparison of ictal and nonictal electrophysiological features. Results: In this small retrospective study (N = 19), responsive corticothalamic neurostimulation was an effective therapy for 79% of patients (≥50% reduction in disabling seizure frequency), regardless of whether the thalamic lead was implanted in the ANT (N = 2), PUL (N = 6), or centromedian nucleus (N = 11). Twenty-six percent of patients reported a reduction in disabling seizure frequency ≥90%. Both high frequency (≥100 Hz) and low (≤20 Hz) frequency were used to stimulate the thalamus depending on the patient's response and ability to tolerate higher charge densities. In all patients, a longer burst duration (2000–5000 ms) was ultimately implemented on the thalamic leads. Across patients, peaks in the intracranial EEG were observed at theta, beta, gamma, and sleep spindle frequencies. Changes in frequency content and distribution were observed over time in all three nuclei. Conclusions: These results indicate that both high frequency and low frequency corticothalamic responsive neurostimulation can potentially be an effective adjunctive therapy in drug-resistant focal epilepsy. These data can also contribute to a broader understanding of thalamic electrophysiology in the context of focal epilepsy.


  • Open Access

    Highlights From the Annual Meeting of the American Epilepsy Society 2022

    by Ignacio Valencia, Allyson L. Alexander, Danielle M. Andrade, Miguel Arevalo-Astrada, Clio Rubiños, Nancy Auer, Jacquelyn L. Bainbridge, Sallie A. Baxendale, Fabrice Bartolomei, Danielle A. Becker, et al.

    With more than 6000 attendees between in-person and virtual offerings, the American Epilepsy Society Meeting 2022 in Nashville, felt as busy as in prepandemic times. An ever-growing number of physicians, scientists, and allied health professionals gathered to learn a variety of topics about epilepsy. The program was carefully tailored to meet the needs of professionals with different interests and career stages. This article summarizes the different symposia presented at the meeting. Basic science lectures addressed the primary elements of seizure generation and pathophysiology of epilepsy in different disease states. Scientists congregated to learn about anti-seizure medications, mechanisms of action, and new tools to treat epilepsy including surgery and neurostimulation. Some symposia were also dedicated to discuss epilepsy comorbidities and practical issues regarding epilepsy care. An increasing number of patient advocates discussing their stories were intertwined within scientific activities. Many smaller group sessions targeted more specific topics to encourage member participation, including Special Interest Groups, Investigator, and Skills Workshops. Special lectures included the renown Hoyer and Lombroso, an ILAE/IBE joint session, a spotlight on the impact of Dobbs v. Jackson on reproductive health in epilepsy, and a joint session with the NAEC on coding and reimbursement policies. The hot topics symposium was focused on traumatic brain injury and post-traumatic epilepsy. A balanced collaboration with the industry allowed presentations of the latest pharmaceutical and engineering advances in satellite symposia.


  • Open Access

    Brain‐responsive corticothalamic stimulation in the pulvinar nucleus for the treatment of regional neocortical epilepsy: A case series

    by David Burdette, Emily A. Mirro, Michael Lawrence, Sanjay E. Patra

    Drug‐resistant focal epilepsy with regional neocortical seizure onsets originating from the posterior quadrant can be particularly difficult to treat with resective surgery due to the overlap with eloquent cortex. Published reports indicate that corticothalamic treatment targeting the anterior or centromedian nucleus of the thalamus with direct brain‐responsive stimulation may be an effective approach to treat regional neocortical epilepsy. The pulvinar has remained largely unstudied as a neurostimulation target to treat refractory epilepsy. Because the pulvinar has connections with the posterior quadrant, neurostimulation may be effective if applied to seizures originating in this area. We performed a retrospective chart review of patients with regional neocortical seizure onsets in the posterior quadrant treated with the RNS System. Demographics, epilepsy history, clinical seizure frequencies, and neuropsychological testing results were obtained from the chart. Electrocorticogram (ECoG) records stored by the RNS System were reviewed to evaluate electrographic seizure onset patterns. Our patients were followed for 10, 12.5, and 15 months. All patients were responders (≥50% seizure reduction), and two of the three patients experienced a ≥90% reduction in seizures at the last follow‐up. Pre‐ and postsurgical neuropsychological evaluations were compared for two of the patients, and there was no evidence of cognitive decline found in either patient. Interestingly, mild cognitive improvements were reported. The third patient had only postimplant neuropsychological testing data available. Findings for this patient suggested executive dysfunction that was present prior to the RNS System which did not worsen with surgery. A visual inspection of ECoGs revealed near‐simultaneous seizure onsets in neocortical and pulvinar leads in two patients. Seizure onsets in the third patient were more variable. This is the first published report of brain‐responsive neurostimulation targeting the pulvinar to treat refractory regional onset epilepsy of posterior quadrant origin.


  • Open Access

    Brain‐Responsive Neurostimulation for the treatment of adults with epilepsy in tuberous sclerosis complex: A case series

    by Danielle S. McDermott, Emily A. Mirro, Kirsten Fetrow, David E. Burdette, Stephanie Chen, Jennifer Hopp, Todd Masel, Emily A. Johnson, Felicia M. K. Elefant, Scheherazade Le, et al.

    Objective: Tuberous sclerosis complex (TSC) is a genetic disorder primarily characterized by the development of multisystem benign tumors. Epilepsy is the most common neurologic manifestation, affecting 80%‐90% of TSC patients. The diffuse structural brain abnormalities and the multifocal nature of epilepsy in TSC pose diagnostic challenges when evaluating patients for epilepsy surgery.Methods: We retrospectively reviewed the safety experience and efficacy outcomes of five adult TSC patients who were treated with direct brain‐responsive neurostimulation (RNS System, NeuroPace, Inc).Results: The average follow‐up duration was 20 months. All five patients were responders (≥50% disabling seizure reduction) at last follow‐up. The median reduction in disabling seizures was 58% at 1 year and 88% at last follow‐up. Three of the five patients experienced some period of seizure freedom ranging from 3 months to over 1 year.Significance: In this small case series, we report the first safety experience and efficacy outcomes in patients with TSC‐associated drug‐resistant focal epilepsy treated with direct brain‐responsive neurostimulation.


  • Open Access

    Brain-responsive corticothalamic stimulation in the centromedian nucleus for the treatment of regional neocortical epilepsy

    by David E. Burdette, M. Ayman Haykal, Beata Jarosiewicz, Rachel R. Fabris, Gabe Heredia, Kost Elisevich, Sanjay E. Patra


  • Open Access

    Expert opinion: Proposed diagnostic and treatment algorithms for Lennox–Gastaut syndrome in adult patients

    by Georgia Montouris, Sami Aboumatar, David Burdette, Sanjeev Kothare, Ruben Kuzniecky, William Rosenfeld, Steve Chung